TY - JOUR
T1 - Corticotropin-releasing factor-induced production of cyclic AMP by human peripheral blood immunocytes
AU - Singh, Vijendra K.
AU - Leu, Sy Jye Christine
PY - 1993
Y1 - 1993
N2 - The immunomodulating properties of a neuropeptide hormone, corticotropin-releasing factor (CRF), led us to investigate its effect on cAMP production by human peripheral blood mononuclear cells (MNC). In response to stimulation with CRF (100 nM), a statistically significant (P = 0.019) increase occurred in the amount of cAMP produced by MNC. Purified monocytes, but not lymphocytes, also displayed a significant (P = 0.01) increase (8- to 10-fold) in intracellular cAMP after treatment with CRF (100 nM). The antagonist α-helical CRF9-41 (100 nM) counteracted the cAMP increase induced by CRF (100 nM). The CRF-induced cAMP production was augmented by pretreatment of MNC with a cAMP-dependent protein kinase (PKA) peptide inhibitor (PI20), but was virtually unaffected by the protein kinase C (PKC) inhibitor H7, suggesting a role for cAMP signalling. Moreover, the CRF-stimulated cAMP level was reduced to baseline by intracellular Ca2+ antagonist HA1004, indicating a role for Ca2+-signalling. Based on these findings, it is concluded that cAMP and/or Ca2+ play a second messenger role in the CRF signal transduction pathway.
AB - The immunomodulating properties of a neuropeptide hormone, corticotropin-releasing factor (CRF), led us to investigate its effect on cAMP production by human peripheral blood mononuclear cells (MNC). In response to stimulation with CRF (100 nM), a statistically significant (P = 0.019) increase occurred in the amount of cAMP produced by MNC. Purified monocytes, but not lymphocytes, also displayed a significant (P = 0.01) increase (8- to 10-fold) in intracellular cAMP after treatment with CRF (100 nM). The antagonist α-helical CRF9-41 (100 nM) counteracted the cAMP increase induced by CRF (100 nM). The CRF-induced cAMP production was augmented by pretreatment of MNC with a cAMP-dependent protein kinase (PKA) peptide inhibitor (PI20), but was virtually unaffected by the protein kinase C (PKC) inhibitor H7, suggesting a role for cAMP signalling. Moreover, the CRF-stimulated cAMP level was reduced to baseline by intracellular Ca2+ antagonist HA1004, indicating a role for Ca2+-signalling. Based on these findings, it is concluded that cAMP and/or Ca2+ play a second messenger role in the CRF signal transduction pathway.
KW - cAMP
KW - Corticotropin-releasing factor
KW - Immunomodulation
KW - Neuroendocrine-immune axis
KW - Neurohormone
KW - Neuropeptide
UR - http://www.scopus.com/inward/record.url?scp=0027463271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027463271&partnerID=8YFLogxK
U2 - 10.1016/0165-2478(93)90189-9
DO - 10.1016/0165-2478(93)90189-9
M3 - Article
C2 - 8390400
AN - SCOPUS:0027463271
SN - 0165-2478
VL - 35
SP - 239
EP - 245
JO - Immunology Letters
JF - Immunology Letters
IS - 3
ER -